Figure 1




Figure 2



1600
1200
800
400
0
APD90 (msec)
ATX II
ATX II
Control
ATX II
+ Compound 1
0
10
20
30
40
Number of consecutive APs

Figure 3



Subject 3103 (30 mg)
(ΔKPQ, nadolol)
650
600
550
500
QTcF, msec
Before dosing (Day -1)
After dosing (Day 1)
0
2
4
6
8
10
12
Time, hrs

Figure 4




60 mg (n=4)
30 mg (n=3)
20 mg (n=3)
10 mg (n=3)
Plasma Concentration of Compound 1, ng/mL
600
400
200
0
0
2
4
6
8
10
12
Time, hr

Figure 5



Shown are mean ± standard error (n=6)

Figure 6




Maximal Time-matched QTc
Change from Baseline (msec)
0
-50
-100
-150
Day 2 (40 mg)
Day 7 (6 mg)

Figure 7


a. ctrl
MAP
ECG
b. E-4031 (60 nM)
MAP
ECG
c. E-4031+Compound 1 (100 nM)
MAP
ECG
d. E-4031+Coupound 1 (300 nM)
MAP
ECG




Incidence of AF (%)
100
75
50
25
0
50%
E-4031
100
300
1000
3000
10000
E-4031+Compound 1 (nM)

Figure 8


A. APD (Dispersion)
APD90, Endo-Epi (msec)
200
150
100
50
0
Control
E-4031 (60 nM)
E-4031+
Compound 1
(300 nM)
500
1000
2000
BCL (msec)
B. QT
QT (msec)
600
400
200
0
500
1000
2000
BCL (msec)
C. TpTe
Tpeak-end (msec)
200
150
100
50
0
500
1000
2000
BCL (msec)